drugset / Trial / NCT00006080

Fenretinide in Treating Patients With Recurrent Malignant Glioma

NCT00006080

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent malignant glioma.

Timeline

Start
2000-09-25
Primary completion
2004-09-14
Completion
2004-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject fenretinide Small molecule 600 mg/m2 Oral
Subject fenretinide Small molecule 900 mg/m2 Oral